Search results
Results from the WOW.Com Content Network
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Special pages; Pages for logged out editors learn more
Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37] Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in ...
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. [3] [4] It is taken by mouth. [3] Side effects of pimavanserin include peripheral edema and confusion. [3]
Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also ...
Antipsychotics are drugs used to treat various symptoms of psychosis, such as those caused by psychotic disorders or schizophrenia. Atypical antipsychotics are also used as mood stabilizers in the treatment of bipolar disorder , and they can augment the action of antidepressants in major depressive disorder . [ 22 ]
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
Fluphenazine, sold under the brand name Prolixin among others, is a high-potency typical antipsychotic medication. [2] It is used in the treatment of chronic psychoses such as schizophrenia, [2] [3] and appears to be about equal in effectiveness to low-potency antipsychotics like chlorpromazine. [4]
For all antipsychotics, the British National Formulary recommends a gradual dose reduction when discontinuing to avoid acute withdrawal syndrome or rapid relapse. [22] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [23] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [23]